2023 - Research.com Medicine in Netherlands Leader Award
His scientific interests lie mostly in Multiple sclerosis, Magnetic resonance imaging, Surgery, Internal medicine and Pathology. Chris H. Polman works on Multiple sclerosis which deals in particular with Expanded Disability Status Scale. The Multiple sclerosis functional composite research Chris H. Polman does as part of his general Expanded Disability Status Scale study is frequently linked to other disciplines of science, such as Concurrent validity, therefore creating a link between diverse domains of science.
His study in Magnetic resonance imaging is interdisciplinary in nature, drawing from both Differential diagnosis, Myelin, Remyelination and Proteolipid protein 1. The concepts of his Internal medicine study are interwoven with issues in Gastroenterology, Placebo and Endocrinology. His Pathology research is multidisciplinary, incorporating elements of Axonal loss, Central nervous system and Brain mapping.
The scientist’s investigation covers issues in Multiple sclerosis, Magnetic resonance imaging, Internal medicine, Pathology and Immunology. A large part of his Multiple sclerosis studies is devoted to Expanded Disability Status Scale. His Magnetic resonance imaging research includes elements of Lesion, Nuclear medicine, Neurology, Atrophy and Spinal cord.
His Internal medicine research includes themes of Gastroenterology, Placebo and Endocrinology. His work carried out in the field of Pathology brings together such families of science as Axonal loss, Myelin, Central nervous system and White matter. His research investigates the connection between Surgery and topics such as Clinically isolated syndrome that intersect with issues in McDonald criteria and Interferon beta-1b.
His primary areas of investigation include Multiple sclerosis, Internal medicine, Magnetic resonance imaging, Physical therapy and Neuroscience. His Multiple sclerosis study integrates concerns from other disciplines, such as Atrophy and Pathology. His Internal medicine study incorporates themes from Surgery, Cardiology, Gastroenterology, Placebo and Interferon beta-1b.
His Magnetic resonance imaging study combines topics in areas such as Evidence-based medicine, Evidence-based practice and Nuclear medicine. The various areas that Chris H. Polman examines in his Physical therapy study include Glatiramer acetate, Randomized controlled trial, Physical medicine and rehabilitation and Clinical trial. His Clinically isolated syndrome research incorporates themes from Vitamin D and neurology, McDonald criteria and Predictive value of tests.
His primary scientific interests are in Multiple sclerosis, Magnetic resonance imaging, Internal medicine, Surgery and Neuroscience. His Multiple sclerosis research is mostly focused on the topic Natalizumab. The Internal medicine study combines topics in areas such as Lesion, Placebo and Cardiology.
His Surgery research incorporates elements of Expanded Disability Status Scale and Clinically isolated syndrome. His Clinically isolated syndrome study combines topics from a wide range of disciplines, such as Predictive value of tests and Interferon beta-1b. When carried out as part of a general Neuroscience research project, his work on Resting state fMRI, Cognition and Neuroimaging is frequently linked to work in Magnetoencephalography and Power graph analysis, therefore connecting diverse disciplines of study.
This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.
Diagnostic criteria for multiple sclerosis: 2010 Revisions to the McDonald criteria
Chris H Polman;Stephen C Reingold;Brenda Banwell;Michel Clanet.
Annals of Neurology (2011)
Recommended diagnostic criteria for multiple sclerosis: Guidelines from the International Panel on the Diagnosis of Multiple Sclerosis
W. Ian McDonald;Alistair Compston;Gilles Edan;Donald E Goodkin.
Annals of Neurology (2001)
Diagnostic criteria for multiple sclerosis: 2005 revisions to the "McDonald Criteria".
Chris H. Polman;Stephen C. Reingold;Gilles Edan;Massimo Filippi.
Annals of Neurology (2005)
A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis
Chris H. Polman;Eva Havrdova;Michael Hutchinson;Ludwig Kappos.
The New England Journal of Medicine (2006)
A Placebo-Controlled Trial of Oral Fingolimod in Relapsing Multiple Sclerosis
Ludwig Kappos;Ernst Wilhelm Radue;Paul O'Connor;Chris Polman.
The New England Journal of Medicine (2010)
Defining the clinical course of multiple sclerosis: The 2013 revisions
Fred D. Lublin;Stephen C. Reingold;Jeffrey A. Cohen;Gary R. Cutter.
Comparison of MRI criteria at first presentation to predict conversion to clinically definite multiple sclerosis.
Frederik Barkhof;Massimo Filippi;David H. Miller;Philip Scheltens.
Oral Fingolimod (FTY720) for Relapsing Multiple Sclerosis
Ludwig Kappos;Jack Antel;Giancarlo Comi;Xavier Montalban.
The New England Journal of Medicine (2006)
Meta-analysis of genome scans and replication identify CD6, IRF8 and TNFRSF1A as new multiple sclerosis susceptibility loci
Philip L De Jager;Philip L De Jager;Xiaoming Jia;Joanne Wang;Paul I W de Bakker.
Nature Genetics (2009)
Treatment with interferon beta-1b delays conversion to clinically definite and McDonald MS in patients with clinically isolated syndromes
L. Kappos;C.H. Polman;M.S. Freedman;G. Edan.
American Journal of Ophthalmology (2007)
If you think any of the details on this page are incorrect, let us know.
We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below: